2018 Press Releases

Keyword Search
 

2018 | 2017 | 2016
DateTitle 
07/12/18Avinger Announces Pricing of $3.55 Million Registered Direct Offering
REDWOOD CITY, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 2,166,180 shares of common stock at a price of $1.6425 per share in a registered direct offering, resulting in total gross proceeds of approximately $3.55 million. The Company also a... 
Printer Friendly Version
07/10/18Avinger Appoints Jaafer Golzar, MD, FACC, FSCAI, as Chief Medical Officer
Practicing Interventional Cardiologist is a Key Opinion Leader in the Treatment of Peripheral Artery Disease REDWOOD CITY, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the appointment, effective immediately, of Jaafer Golzar, MD, as the Company’s Chief Medical Officer. Dr. Golzar provides Avinger with an extensive and impressive history of clinical leadership within the ... 
Printer Friendly Version
06/26/18Avinger Announces Successful Treatment of First Patients with Next-Generation Pantheris in Several Centers throughout the US
REDWOOD CITY, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that several physicians have successfully treated over 40 patients in the US across 13 sites with the next-generation Pantheris image-guided atherectomy system for the treatment of peripheral artery disease (PAD). This positive initial case experience in the US adds to the impressive clinical results achieved in t... 
Printer Friendly Version
06/21/18Avinger’s Ocelot Technology Featured in Live Case Transmission at Complex Cardiovascular Catheter Therapeutics (C3) 2018
C3 Curriculum Designed for Physicians Specializing in Interventional Cardiology, Vascular Surgery and Interventional Radiology REDWOOD CITY, Calif., June 21, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that its Ocelot image-guided chronic total occlusion (CTO) crossing device was featured in a live case on June 19th at Complex Cardiovascular Catheter Therapeutics (C3) 2018 in Orlando, F... 
Printer Friendly Version
06/14/18Avinger Announces First Patients Enrolled in Post-Market Study Comparing Pantheris OCT Imaging to Intravascular Ultrasound
SCAN Clinical Trial Results Intended to Support CPT Code Application for Incremental Diagnostic Reimbursement REDWOOD CITY, Calif., June 14, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the initiation of the SCAN study, a post-market study comparing optical coherence tomography (OCT) with intravascular ultrasound (IVUS) as a diagnostic imaging tool in the peripheral arteries. OCT is a li... 
Printer Friendly Version
06/13/18Avinger Appoints Mark Weinswig as Chief Financial Officer
REDWOOD CITY, Calif., June 13, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that Mark Weinswig will join the Company, and serve in the role of Chief Financial Officer (CFO) effective June 25, 2018. Mr. Weinswig will succeed Matt Ferguson, who will be leaving the Company to pursue other opportunities. Mr.  Ferguson will remain a full-time employee of Avinger un... 
Printer Friendly Version
05/30/18Avinger Announces Presentations and Posters Featuring Lumivascular Technology at New Cardiovascular Horizons Annual Conference
REDWOOD CITY, Calif., May 30, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced a schedule of sessions and posters highlighting the company’s Lumivascular technology at the New Cardiovascular Horizons (NCVH) annual conference taking place this week in New Orleans, Louisiana, from Tuesday, May 29, through Friday, June 1, 2018. Avinger Lumivascular technology highlights include the following ... 
Printer Friendly Version
05/29/18Avinger to Present at the 8th Annual LD Micro Invitational
REDWOOD CITY, Calif., May 29, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that it will be presenting at the 8th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Bel Air, California. The conference will be held on June 4-6, 2018. Mr. Jeff Soinski, Avinger’s President and CEO will be presenting on Monday, June 4 at 1:30 pm Pacific time, with one-on-one meetings held th... 
Printer Friendly Version
05/23/18Avinger Receives FDA Clearance of Next Generation Pantheris Device
The Pantheris Lumivascular Atherectomy System is the first-ever image-guided atherectomy device for treatment of peripheral artery disease REDWOOD CITY, Calif., May 23, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its next generation Pantheris® Lumivascular atherectomy system, the first-ever... 
Printer Friendly Version
05/14/18Avinger Announces First Quarter 2018 Financial Results
REDWOOD CITY, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the first quarter ended March 31, 2018.   First Quarter and Recent Highlights Revenue of $1.8 million for the first quarter of 2018 Announced treatment of first patients globally with next generation Pantheris Lumivascular atherectomy system   Added the extended nosecone version of next gen... 
Printer Friendly Version
05/04/18Avinger to Announce First Quarter 2018 Financial Results on May 14, 2018
REDWOOD CITY, Calif., May 04, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the first quarter 2018 after the close of trading on Monday, May 14, 2018. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET. Individuals interested in listening to the conference call may do so by dialing (877) 407-8293 for dome... 
Printer Friendly Version
04/30/18Avinger’s Next Generation Pantheris Featured in Live Case Transmission at Charing Cross International Symposium 2018
Charing Cross Symposium (CX) is the longest running vascular and endovascular symposium in Europe and one of the largest in the world REDWOOD CITY, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that its next generation Pantheris® Lumivascular atherectomy system with extended nosecone was featured in a live case transmission at Charing Cross Symposium (CX) 2018 held in London, ... 
Printer Friendly Version
03/29/18Avinger Announces First-in-Patient use of Extended Nosecone Version of Next Generation Pantheris
Three patients successfully treated using next generation image-guided atherectomy device with enhanced tissue removal capacity for treatment of peripheral artery disease REDWOOD CITY, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that Arne Schwindt, M.D., a vascular surgeon at St. Franziskus Hospital in Münster, Germany, successfully treated the first three patients wit... 
Printer Friendly Version
03/19/18Avinger Announces Fourth Quarter and Full Year 2017 Results
REDWOOD CITY, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the fourth quarter and full year ended December 31, 2017. Fourth Quarter and Recent Highlights Revenue of $1.9 million for the fourth quarter of 2017 and $9.9 million for full year 2017 Submitted FDA 510(k) application for the next generation Pantheris image-guid... 
Printer Friendly Version
03/13/18Avinger Provides Update on U.S. Intellectual Property Portfolio
Three New Patents Allowed or Issued for Proprietary CTO Crossing Devices REDWOOD CITY, Calif., March 13, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced three recent additions to its U.S. intellectual property portfolio. The U.S. Patent and Trademark Office ("USPTO") has issued U.S. Patent No. 9,854,979, titled “Chronic Total Occlusion Crossing Devices with Imaging.” In addition, the USP... 
Printer Friendly Version
03/06/18Avinger to Announce Fourth Quarter 2017 and Full Year 2017 Results on March 19th, 2018
REDWOOD CITY, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the fourth quarter and full year 2017 after the close of trading on Monday, March 19, 2018. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET. Individuals interested in listening to the conference call may do so by dialing (844... 
Printer Friendly Version
03/05/18Avinger Announces Participation in Cowen and Company 38th Annual Health Care Conference
REDWOOD CITY, Calif, March 05, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that the Company will be participating in the Cowen and Company 38th Annual Health Care Conference in Boston. Avinger management is scheduled to present on Wednesday, March 14, 2018 at 9:20am ET. Interested parties can access the live audio webcast with accompanying slides from the Events section of Avinger’s w... 
Printer Friendly Version
03/02/18Avinger Regains Compliance with Nasdaq Listing Requirements
REDWOOD CITY, Calif., March 02, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced it has regained compliance with Nasdaq listing requirements.  In a letter dated March 1, 2018, Nasdaq informed the Company that it has achieved compliance with the minimum bid price rule, the market value of publicly held shares rule and the market value of listed securities rule, as required by the Nasdaq Hea... 
Printer Friendly Version
02/20/18OPS Code Established for Peripheral Vascular OCT Imaging in Germany
New Code is a Potential Precursor to Higher Reimbursement Levels in German DRG System REDWOOD CITY, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that the German Institute for Medical Documentation and Information (DIMDI, Cologne) has established a tracking code, known as an OPS code (Operationen- and Prozedurenschluessel), for peripheral vascular optical coherence tomography (... 
Printer Friendly Version
02/16/18Avinger Announces Closing of $18 Million Underwritten Public Offering
Secured Lenders Convert $38 Million of Debt into Equity REDWOOD CITY, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the closing of an underwritten public offering of Series B convertible preferred stock, together with warrants, for gross proceeds of approximately $18.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Avin... 
Printer Friendly Version
02/14/18Avinger Announces Pricing of $18 Million Underwritten Public Offering
Secured Lenders Convert $38 Million of Debt into Equity REDWOOD CITY, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the pricing of an underwritten public offering of Series B convertible preferred stock, together with warrants, for gross proceeds of $18.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Avinger. In conjun... 
Printer Friendly Version
02/02/18Avinger’s Next Generation Pantheris Featured in Live Case Transmission at Leipzig Interventional Course 2018
Leipzig Interventional Course is a leading global forum for new methods and technology in the field of vascular medicine REDWOOD CITY, Calif., Feb. 02, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that its next generation Pantheris® Lumivascular atherectomy system was featured in a live case transmission at Leipzig Interventional Course (LINC) 2018 held from January 30th through February 2nd a... 
Printer Friendly Version
01/30/18Avinger Announces Reverse Stock Split
REDWOOD CITY, Calif., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that the Company will effect a 1-for-40 reverse stock split of the Company's common stock, which will be effective at 5:00 p.m. Eastern time on Tuesday, January 30, 2018. As of that date, each 40 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. A new C... 
Printer Friendly Version
01/19/18Avinger Granted Continued Listing Decision From Nasdaq
REDWOOD CITY, Calif., Jan. 19, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company has received formal notification that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for the transfer of its listing from The Nasdaq Global Market to The Nasdaq Capital Market, pursuant to an extension through March 31, 2018 to evidence compliance with all applicable req... 
Printer Friendly Version
01/03/18Avinger Announces Treatment of First Patients Globally With Next Generation Pantheris
Seven patients successfully treated using next generation image-guided atherectomy device for treatment of peripheral artery disease REDWOOD CITY, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that Arne Schwindt, M.D., a vascular surgeon at St. Franziskus Hospital in Münster, Germany, has successfully treated the first seven patients with the next generation Pantheris Lumivascu... 
Printer Friendly Version